Back to homepage

Nephrology and Urology

Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs

Authors: Alessandro Roggeri BSc, Ferruccio Conte MD, Carlotta Rossi MSc, Mario Cozzolino MD, PhD, Carlo Zocchetti MSc, Daniela Paola Roggeri MSc

This retrospective observational study evaluated, in dialysis patients with SHPT, the impact of different levels of adherence to cinacalcet therapy on hospitalisations and direct healthcare costs charged to the Lombardy Regional Health Service (Italy).

More

HIV, drugs and the kidney

Authors: Nicola Wearne MBChB, FCP, MMed, Bianca Davidson MBChB, FCP, MMed, Marc Blockman MBChB, BPharm, PG Dip Int Res Ethics, MMed, Annoesjka Swart BScPharm, Erika SW Jones MBBCh, FCP, PhD

This review discusses antiretroviral therapy and its nephrotoxic effects, including drug–drug interactions. It aims to guide the clinician on dose adjustment in the setting of renal impairment and dialysis, for the commonly used drugs in patients with HIV.

More

Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues

Authors: Ashutosh M Shukla MD, Aparna Wagle Shukla MD

This article reviews the expanding clinical applicability of chloroquine and related drugs includes rheumatological and cardiovascular disorders (CVD), chronic kidney disease (CKD), oncology, and a variety of nonmalarial infections.

More

Immunotherapy in renal cell carcinoma: latest evidence and clinical implications

Authors: Matteo Santoni MD, Francesco Massari MD, Vincenzo Di Nunno MD, Alessandro Conti MD, Alessia Cimadamore MD, Marina Scarpelli MD, Rodolfo Montironi PhD, Liang Cheng PhD, Nicola Battelli MD, Antonio Lopez-Beltran PhD

This editorial describes the results of the most recent clinical trials on the use of immunotherapies in renal cell carcinoma and research for reliable biomarkers of tumour response in this setting, as well as the role of the gut microbiome and tumour microenvironment in the development of future therapeutic strategies.

More

NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK

Authors: Helene Cawston, Francois Bourhis, Jennifer Eriksson, Pierfrancesco Ruffo, Paolo D’Agostino, Marco Turini, Lee Schwartzberg, Alistair McGuire

Despite study limitations (study setting, time horizon, utility measure), the results suggest NEPA is cost effective for preventing CINV associated with HEC and MEC in the UK.

More